CN102209713B - 作为5-羟色胺-6配体的1-(芳磺酰基)-4-(哌嗪-1-基)-1h-苯并咪唑 - Google Patents

作为5-羟色胺-6配体的1-(芳磺酰基)-4-(哌嗪-1-基)-1h-苯并咪唑 Download PDF

Info

Publication number
CN102209713B
CN102209713B CN200980144578.1A CN200980144578A CN102209713B CN 102209713 B CN102209713 B CN 102209713B CN 200980144578 A CN200980144578 A CN 200980144578A CN 102209713 B CN102209713 B CN 102209713B
Authority
CN
China
Prior art keywords
benzimidazole
alkyl
sulfonyl
compound
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980144578.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102209713A (zh
Inventor
S·N·海达尔
P·M·安德烈
H·云
A·J·罗比乔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41404503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102209713(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN102209713A publication Critical patent/CN102209713A/zh
Application granted granted Critical
Publication of CN102209713B publication Critical patent/CN102209713B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/22—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200980144578.1A 2008-11-11 2009-11-10 作为5-羟色胺-6配体的1-(芳磺酰基)-4-(哌嗪-1-基)-1h-苯并咪唑 Expired - Fee Related CN102209713B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11329608P 2008-11-11 2008-11-11
US61/113,296 2008-11-11
PCT/US2009/063816 WO2010056644A1 (en) 2008-11-11 2009-11-10 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS

Publications (2)

Publication Number Publication Date
CN102209713A CN102209713A (zh) 2011-10-05
CN102209713B true CN102209713B (zh) 2014-07-02

Family

ID=41404503

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980144578.1A Expired - Fee Related CN102209713B (zh) 2008-11-11 2009-11-10 作为5-羟色胺-6配体的1-(芳磺酰基)-4-(哌嗪-1-基)-1h-苯并咪唑

Country Status (41)

Country Link
US (1) US8063053B2 (cg-RX-API-DMAC10.html)
EP (1) EP2285784B1 (cg-RX-API-DMAC10.html)
JP (1) JP5087171B2 (cg-RX-API-DMAC10.html)
KR (1) KR101323417B1 (cg-RX-API-DMAC10.html)
CN (1) CN102209713B (cg-RX-API-DMAC10.html)
AP (1) AP2814A (cg-RX-API-DMAC10.html)
AR (1) AR074325A1 (cg-RX-API-DMAC10.html)
AU (1) AU2009314221B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0920682A2 (cg-RX-API-DMAC10.html)
CA (1) CA2740262C (cg-RX-API-DMAC10.html)
CL (1) CL2011001050A1 (cg-RX-API-DMAC10.html)
CO (1) CO6440548A2 (cg-RX-API-DMAC10.html)
CR (1) CR20110247A (cg-RX-API-DMAC10.html)
CU (1) CU24020B1 (cg-RX-API-DMAC10.html)
CY (1) CY1113025T1 (cg-RX-API-DMAC10.html)
DK (1) DK2285784T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2011000130A (cg-RX-API-DMAC10.html)
EA (1) EA018369B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP11011045A (cg-RX-API-DMAC10.html)
ES (1) ES2389694T3 (cg-RX-API-DMAC10.html)
GE (1) GEP20135805B (cg-RX-API-DMAC10.html)
HR (1) HRP20120561T1 (cg-RX-API-DMAC10.html)
IL (1) IL212213A0 (cg-RX-API-DMAC10.html)
MA (1) MA32788B1 (cg-RX-API-DMAC10.html)
ME (1) ME01129B (cg-RX-API-DMAC10.html)
MX (1) MX2011004996A (cg-RX-API-DMAC10.html)
MY (1) MY156324A (cg-RX-API-DMAC10.html)
NI (1) NI201100093A (cg-RX-API-DMAC10.html)
NZ (1) NZ592563A (cg-RX-API-DMAC10.html)
PE (1) PE20120026A1 (cg-RX-API-DMAC10.html)
PL (1) PL2285784T3 (cg-RX-API-DMAC10.html)
PT (1) PT2285784E (cg-RX-API-DMAC10.html)
RS (1) RS52381B (cg-RX-API-DMAC10.html)
SA (1) SA109300673B1 (cg-RX-API-DMAC10.html)
SI (1) SI2285784T1 (cg-RX-API-DMAC10.html)
SV (1) SV2011003902A (cg-RX-API-DMAC10.html)
TN (1) TN2011000203A1 (cg-RX-API-DMAC10.html)
TW (1) TWI481605B (cg-RX-API-DMAC10.html)
UA (1) UA100192C2 (cg-RX-API-DMAC10.html)
WO (1) WO2010056644A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201103283B (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951805B2 (en) * 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP1804799B1 (en) * 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101083986A (zh) * 2004-09-20 2007-12-05 泽农医药公司 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途
CA2580856A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN104557726B (zh) * 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
AU2015286049B2 (en) 2014-07-08 2018-03-01 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
WO2021021951A1 (en) 2019-07-29 2021-02-04 Vanderbilt University Wdr5-myc inhibitors
EP4121413A4 (en) * 2020-04-22 2024-04-17 Recurium IP Holdings, LLC PREPARATION OF A SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENT

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1484638A (zh) * 2000-11-02 2004-03-24 作为5-羟色胺-6配体的1-芳基-或1-烷基磺酰基-杂环基吲哚
CN1694866A (zh) * 2001-06-15 2005-11-09 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
CN1714077A (zh) * 2000-10-20 2005-12-28 比奥维特罗姆股份公司 2－、3－、4－或5－取代的n1－(苯磺酰基)吲哚及其治疗用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
IL133870A0 (en) 1997-07-11 2001-04-30 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
DK0930302T3 (da) 1998-01-16 2003-07-21 Hoffmann La Roche Benzosulfonderivater
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
ES2192394T3 (es) * 1998-08-10 2003-10-01 Winston Pharmateuticals Llc Profarmacos de inhibidores de la bomba de protones.
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
KR100823908B1 (ko) * 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
MXPA03011638A (es) * 2001-06-15 2004-04-02 Hoffmann La Roche Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
WO2003026665A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
AU2003284142A1 (en) 2002-10-15 2004-05-04 Synta Pharmaceuticals Corp Aromatic bicyclic heterocyles to modulate 1L-12 production
TWI380816B (zh) 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑
RU2007107177A (ru) 2004-07-28 2008-09-10 Айрм Ллк (Bm) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1714077A (zh) * 2000-10-20 2005-12-28 比奥维特罗姆股份公司 2－、3－、4－或5－取代的n1－(苯磺酰基)吲哚及其治疗用途
CN1484638A (zh) * 2000-11-02 2004-03-24 作为5-羟色胺-6配体的1-芳基-或1-烷基磺酰基-杂环基吲哚
CN1694866A (zh) * 2001-06-15 2005-11-09 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物

Also Published As

Publication number Publication date
EA018369B1 (ru) 2013-07-30
HRP20120561T1 (hr) 2012-07-31
DK2285784T3 (da) 2012-07-23
CO6440548A2 (es) 2012-05-15
TN2011000203A1 (fr) 2012-12-17
MX2011004996A (es) 2011-05-25
CA2740262C (en) 2013-05-28
SV2011003902A (es) 2011-07-05
TWI481605B (zh) 2015-04-21
JP2012508275A (ja) 2012-04-05
CY1113025T1 (el) 2016-04-13
CN102209713A (zh) 2011-10-05
PL2285784T3 (pl) 2012-12-31
RS52381B (sr) 2012-12-31
EP2285784B1 (en) 2012-07-04
NI201100093A (es) 2011-10-31
CL2011001050A1 (es) 2011-08-19
CU20110101A7 (es) 2012-01-31
SI2285784T1 (sl) 2012-08-31
CR20110247A (es) 2011-06-24
AP2814A (en) 2013-12-31
PT2285784E (pt) 2012-09-19
JP5087171B2 (ja) 2012-11-28
AU2009314221B2 (en) 2012-08-30
GEP20135805B (en) 2013-04-10
ES2389694T3 (es) 2012-10-30
KR20110075013A (ko) 2011-07-05
AP2011005664A0 (en) 2011-04-30
ME01129B (me) 2013-03-20
ECSP11011045A (es) 2011-06-30
HK1158647A1 (en) 2012-07-20
TW201022247A (en) 2010-06-16
US20100120779A1 (en) 2010-05-13
AR074325A1 (es) 2011-01-05
UA100192C2 (en) 2012-11-26
KR101323417B1 (ko) 2013-10-29
CU24020B1 (es) 2014-07-30
MY156324A (en) 2016-02-15
WO2010056644A8 (en) 2010-11-18
AU2009314221A1 (en) 2010-05-20
MA32788B1 (fr) 2011-11-01
SA109300673B1 (ar) 2013-05-25
IL212213A0 (en) 2011-06-30
EP2285784A1 (en) 2011-02-23
WO2010056644A1 (en) 2010-05-20
BRPI0920682A2 (pt) 2016-09-27
PE20120026A1 (es) 2012-02-12
US8063053B2 (en) 2011-11-22
NZ592563A (en) 2012-10-26
EA201100696A1 (ru) 2011-10-31
CA2740262A1 (en) 2010-05-20
DOP2011000130A (es) 2017-04-30
ZA201103283B (en) 2012-01-25

Similar Documents

Publication Publication Date Title
TWI481605B (zh) 作為５－羥色胺－６配位基之１－（芳基磺醯基）－４－（哌－１－基）－１ｈ－苯并咪唑
JP2009538910A (ja) ５−ヒドロキシトリプタミン−６リガンドとしての１−スルホニルインダゾリルアミン誘導体および１−スルホニルインダゾリルアミド誘導体
JPH10101650A (ja) 新規イソキノリン誘導体
US7414051B2 (en) Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
US20070244179A1 (en) Dihydro[1,4]dioxino[2,3-e]indazole derivatives as 5-hydroxytryptamine-6 ligands
JP5146766B2 (ja) ５−ヒドロキシトリプタミン−６リガンドとしての置換−３−スルホニルインダゾール誘導体
MX2008015328A (es) Derivados de benzoxazol y benzotiazol como ligandos de 5-hidroxitriptamina-6.
JP2009504738A (ja) ５−ヒドロキシトリプタミン−６リガンドとしてのアジニル−３−スルホニルインダゾール誘導体
HK1158647B (en) 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazo as 5-hydroxytryptamine-6 ligands
US7939520B2 (en) Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
JP2009532471A (ja) ５−ヒドロキシトリプタミン−６リガンドとしてのスルホニル−３−ヘテロシクリルインダゾール誘導体
US7429582B2 (en) Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands and use thereof in the treatment of attention deficit disorders
US20090318470A1 (en) 1-substituted-3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1h-indazole compounds as 5-hydroxytryptamine-6 ligands

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1158647

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1158647

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140702

Termination date: 20181110

CF01 Termination of patent right due to non-payment of annual fee